Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 388 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Multipronged Approach Eliminates Racial Disparities in Early-Stage Lung Cancer Treatment March 5, 2019 For Some Kids with Brain Cancer, Targeted Therapy is Better than... June 29, 2022 2-Year-Old Cancer Survivor With Down Syndrome Hears For First Time: ‘Her... October 14, 2019 Cancer in My Community: Caring for Children With Cancer in Paraguay June 8, 2023 Load more HOT NEWS 35-Year-Old Mom Has Been Living With Stage IV Breast Cancer For... Utility of Genomic Profiling of cfDNA to Inform Clinical Care for... NEOSTAR Results Indicate that Neoadjuvant Nivolumab Plus Ipilimumab Enhances Pathologic Responses... EMA Recommends Granting a Marketing Authorisation for Tebentafusp
